乳腺癌放疗中佩戴文胸的影响:一项前瞻性随机预试验
该前瞻性随机临床试验将38例保乳术后乳腺癌患者随机分为放疗期间佩戴文胸组与不佩戴组,以每日锥形束CT评估乳房形状可重复性。佩戴组ΔNPD的ε、Σ、σ均显著小于不佩戴组,大罩杯(C-D)患者MSD的ε亦显著更小,两组肺和心脏剂量学结果无显著差异,≥2级毒性均极少。结论认为佩戴文胸可提高乳房形状可重复性,尤其在大乳房患者中,且不增加治疗毒性。
要点
- 佩戴文胸组ΔNPD的ε、Σ、σ均显著小于不佩戴组(P均<0.001)。
- 大罩杯(C-D)患者佩戴组MSD的ε显著更小(1.1 mm vs 2.1 mm,P=0.006)。
- 两组肺和心脏剂量学结果无显著差异,≥2级毒性均极少。
核心结论
- 放疗期间佩戴文胸可提高乳房形状可重复性,尤其在大乳房患者中,且不增加治疗毒性。
研究设计与样本
- 前瞻性随机临床试验,38例保乳术后乳腺癌患者随机分为放疗期间佩戴文胸组与不佩戴组。
- 以每日锥形束CT评估乳房形状可重复性,主要结局为ΔNPD和MSD(每日CBCT与计划CT比较),并计算ε、Σ、σ。
- 次要结局包括剂量学参数和急性/亚急性毒性。
- 试验注册号NCT06178861。
主要发现
- ΔNPD的ε(1.0 mm vs 3.8 mm,P<0.001)、Σ(0.6 mm vs 3.6 mm,P<0.001)、σ(0.8 mm vs 2.2 mm,P<0.001)在佩戴文胸组显著更小。
- 大罩杯(C-D)患者MSD的ε在佩戴组显著更小(1.1 mm vs 2.1 mm,P=0.006),小乳房患者无此差异。
- 绝对ΔNPD超过3 mm的CBCT扫描比例在佩戴组为0.4%、不佩戴组为48.1%(P<0.001)。
- 绝对MSD超过3 mm的扫描比例在佩戴组为2.1%、不佩戴组为10.0%(P<0.001)。
- 两组肺和心脏剂量学结果无显著差异,两组≥2级毒性均极少。
临床怎么用
- 原文结论认为放疗期间佩戴文胸可提高乳房形状可重复性,尤其在大乳房患者中,且不增加治疗毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective, randomized clinical trial evaluated the effects of bra-wearing during radiotherapy on breast-shape reproducibility, dosimetry, and treatment toxicities in patients with breast cancer. METHODS: Thirty-eight patients with breast cancer who underwent breast-conserving surgery were randomly assigned to bra-wearing or non-wearing groups during radiotherapy. Breast-shape reproducibility was assessed using daily cone-beam computed tomography (CBCT). The primary outcome was breast-shape reproducibility, evaluated by the nipple-to-pectoral muscle distance (ΔNPD) and mean surface distance (MSD), comparing daily CBCT to planning CT. We calculated the mean root-mean-squared error (ε), systematic error (Σ), and random error (σ). Secondary outcomes included dosimetric parameters and acute/subacute toxicities. RESULTS: ΔNPD ε (1.0 mm vs 3.8 mm, P < 0.001), Σ (0.6 mm vs 3.6 mm, P < 0.001), and σ (0.8 mm vs 2.2 mm, P < 0.001) were significantly smaller in the bra-wearing group. For larger breasts (cup sizes C-D), MSD ε was significantly smaller in the bra-wearing group (1.1 mm vs. 2.1 mm, P = 0.006), but not for smaller breasts. The absolute ΔNPD exceeded 3 mm in 0.4 % of CBCT scans in the bra-wearing group and 48.1 % in the non-wearing group (P < 0.001). Absolute MSD exceeded 3 mm in 2.1 % and 10.0 % of scans in the bra-wearing and non-wearing groups, respectively (P < 0.001). No significant differences were observed in lung and heart dosimetric outcomes between groups. Grade 2 or higher toxicities were minimal in both groups. CONCLUSION: The use of a bra during radiotherapy enhances breast-shape reproducibility, particularly in patients with larger breasts, without increasing treatment toxicities. TRIAL REGISTRATION NUMBER: NCT06178861.
引用
- Byun HK, Kim H, Son J, et al. Impact of bra application in breast cancer radiotherapy: A pilot prospective randomized trial. Radiother Oncol. 2025. PMID: 39952437. doi:10.1016/j.radonc.2025.110785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。